The Acanthocytosis Chorea Treatment Market is a niche but rapidly evolving segment of the neurodegenerative and rare disease industry. The condition is primarily caused by mutations in the VPS13A gene, leading to the absence of the protein chorein. Because there is currently no curative therapy, the market is driven by pharmacological interventions that manage debilitating symptoms li... https://shashikant873.livejournal.com/3767.html